, autism spectrum disorder (ASD) 3 and congenital heart defects 4 . Whole-exome sequencing (WES) has produced a boon of findings linking de novo mutations to risk for developmental disorders [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Not all mutations are simple to interpret as causing a loss of gene function. Missense mutations are especially difficult; although there are bioinformatics tools to predict the level of damage [20] [21] [22] , these annotators are far from perfect. This is a critical deficiency because the majority of coding mutations are missense. Here we show that one key feature in evaluating the disruptiveness of mutations is whether they fall in known or predicted protein-protein interaction interfaces and their likelihood to disrupt these interactions.
Large-scale studies of known disease-associated mutations have already reported a strong association with binding interfaces of protein interactions 23, 24 . The major bottleneck for wide application of this feature is limited knowledge about the set of interactions and the binding interfaces of all interactions. To experimentally evaluate the impact of mutations on protein interactions, we establish a high-throughput mutagenesis and interactome-scanning pipeline for generating site-specific mutant clones and testing corresponding mutant protein interactions. However, such a pipeline cannot evaluate the impact of missense mutations on many interactions, because high-throughput interaction assays are limited in their coverage [25] [26] [27] . For this reason, we also explore a computational approach for systematically examining the functional impact of missense mutations on protein interactions. This approach builds on our newly established full-interactome interface predictions 28 to computationally predict the impact of all missense mutations on all associated interactions. Here we apply our experimental and computational approaches in tandem, which can be applied to any WES study.
To evaluate the effectiveness of our integrated experimental-computational approach, we focus on 2,821 de novo missense (dnMis) mutations identified from WES of ~2,500 families from the Simons Simplex Collection (SSC) 29 (Supplementary Table 1 ). The SSC targets the study of ASD through a cohort of parent-offspring trios or quads with two unaffected parents, an ASD proband and, for most families, an unaffected sibling 30 . Previous analyses of the SSC data have reported significantly higher de novo mutation rates in ASD probands versus unaffected siblings across various mutation types, from copy-number variants 29, 31, 32 , to frameshift indels 33 , to missense mutations [12] [13] [14] 16 . While a number of risk de novo copynumber 29, 31, 32, 34, 35 and protein-truncating [12] [13] [14] 16, 33 variants have been identified, exactly which dnMis mutations play a role and to what extent are open questions. We applied our integrated framework to evaluate the effect of 1,733 dnMis mutations within a protein interactome framework, aiming to identify potentially disease-contributing dnMis mutations. Although there are many ways by which a missense mutation can impact a protein's function, such as by destabilizing protein folding, we evaluate the disruptiveness of a mutation within our framework exclusively on its capacity to disrupt protein interactions, measured experimentally or through prediction. We further compare the network properties of proteins impacted by interaction-disrupting and non-disrupting dnMis mutations, using unaffected siblings as negative controls throughout. While our analyses focus on dnMis mutations in ASD, the integrated experimental-computational approach provides a generalizable framework for investigating the impact of missense mutations uncovered by WES for human diseases.
An interactome perturbation framework prioritizes damaging missense mutations for developmental disorders Results

Proband dnMis mutations are enriched on interaction interfaces.
We previously reported that inherited in-frame disease-associated mutations are significantly enriched on protein interaction interfaces and demonstrated that alteration of specific protein interactions is crucial in the pathogenesis of many disease-associated genes 36 . To explore the relationship between non-inherited dnMis mutations and autism, we used a structurally resolved three-dimensional human interactome network 36, 37 to examine where dnMis mutations reside with respect to interaction interfaces. We found that in probands, dnMis mutations are significantly enriched on interaction interfaces. While interaction interfaces cover 30.1% of the proteins harboring these mutations, 38.2% of the mutations fall in interaction interfaces (1.27-fold, P = 2.9 × 10 −3 by a two-tailed exact binomial test). In contrast, dnMis mutations in siblings fall in interaction interfaces on corresponding proteins at an expected rate (observed 37.6% versus expected 36.5%, 1.03-fold, P = 0.76). Thus, disruption of specific interactions could contribute to ASD etiology for dnMis mutations in probands (Fig. 1a) , underscoring the functional significance of dnMis mutations on protein interaction interfaces.
Proband dnMis mutations have elevated disruption rates. We next explored the impact of dnMis mutations on protein interactions by intersecting all 2,821 dnMis mutations with 59,073 human protein interactions, a comprehensive set of high-quality physical interactions compiled in HINT 38 from eight widely used interaction databases, including BioGRID 39 , MINT 40 , iRefWeb 41 , DIP 42 , IntAct 43 , HPRD 44 , MIPS 45 and the PDB 46 . Of these mutations, 1,733 are on proteins with at least 1 known interaction within the current human interactome data set. To experimentally assess the impact of a subset of these mutations, 208 individual clones were generated carrying dnMis mutations-corresponding to 109 in probands and 99 in siblings, respectively-using Clone-seq, a massively parallel site-directed mutagenesis pipeline 24 . Protein interactions amenable to yeast two-hybrid (Y2H) were then tested, yielding 667 total protein interactions corresponding to 151 of our cloned dnMis mutations ( Fig. 1b; Methods) .
To explore the remaining dnMis mutations and interactions untested by Y2H, we applied a two-tiered computational approach that first predicts whether a particular residue is an interface residue using Interactome INSIDER 28 , a unified machine-learning framework comprising the first full-interactome map of human interaction interfaces. To determine whether a particular mutation is deleterious, we used PolyPhen-2 (PPH2) 20 predictions: if a particular residue is predicted to be an interface residue and its mutation is scored as 'probably damaging' by PPH2, that mutation was predicted as interaction-disrupting; if a mutation is unlikely to occur at an interface residue and is scored as 'benign' by PPH2, it was predicted as interaction non-disrupting ( Fig. 1b; Methods) .
To evaluate the performance of our computational predictions, we applied this two-tiered prediction approach to our 667 experimentally tested protein interactions and obtained an accuracy of 80.8% (sensitivity: 65.0%, specificity: 82.5%). Moreover, when our approach was applied to a previously published, independent data set of 204 disease-associated mutations and their impact on protein-protein interactions 24 , we obtained a similar prediction performance (accuracy: 77.4%, sensitivity: 81.0%, specificity: 75.0%).
We then analyzed the distribution of disrupted interactions across ASD probands and unaffected siblings. Examining our experimental data showed that 74/361 (20.5%) tested interactions were disrupted in probands. In contrast, only 21 out of 208 (10.1%) interactions were disrupted in unaffected siblings. Modeling the count of disruptions per subject with a negative binomial model, using case status as the predictor, yielded a 2.54-fold higher rate of disruptions in probands (P = 0.012, Fig. 2a and Supplementary Table 2; Methods). This sharp contrast in interaction disruption rate suggests that disruption of the interactome network by dnMis mutations contributes to autism etiology in probands. Combining the experimental data with predictions for all remaining dnMis mutations and interactions, there was again a significant, 2.34-fold higher disruption rate for probands (25.3%) versus unaffected siblings (10.8%, P = 5.6 × 10 −4 , Fig. 2b ). Furthermore, the predicted disruptions alone showed significantly higher rate of disruption in probands than siblings (2.15-fold, P = 0.013, Fig. 2c ). These observations suggest that dnMis mutations in ASD probands are of higher functional consequence than those in unaffected siblings. Therefore, interaction-disrupting mutations identified by our integrated experimentalcomputational framework could serve as a viable approach for identifying candidate risk variants, which may go undetected by other methodologies. Hereinafter, we shall present results using the combined data. Results using only the Y2H data or predictions are provided in Supplementary Fig. 1 . The female protective effect postulates that females require a larger genetic burden before being diagnosed with ASD 7, 47 . Accordingly, we anticipate dnMis mutations in female probands to be more disruptive than those in male probands, although the 6.5:1 male/female ratio of probands could obscure true differences by limiting power. Indeed, we observed a higher disruption rate in females than in males among ASD probands, fold = 1.71, but the difference is not significant (P = 0.12). In contrast, the disruption rate in female versus male siblings is 1.08-fold and does not approach significance (P = 0.42, Fig. 2b ).
Disruptive dnMis mutations in probands impact network hubs.
Previous research has shown that genes harboring known diseaseassociated mutations differ strongly in their network properties in comparison to non-disease-associated genes 48, 49 . Early studies reported that disease-associated genes often encode for protein hubs that mediate a greater number of protein interactions than their non-disease-associated counterparts as a whole 50, 51 . However, researchers later argued that the observed hub-disease gene correlation might be entirely driven by a handful of hub-encoding essential genes classified within the disease-associated gene class 48 . Here we investigated whether proteins harboring disruptive dnMis mutations in ASD probands exhibit distinguishable network properties in the human interactome.
We first compared the degree of all proteins harboring interaction-disrupting dnMis mutations to those harboring non-disrupting dnMis mutations. We found that in ASD probands, proteins with interaction-disrupting dnMis mutations on average have a significantly higher degree than proteins with non-disrupting dnMis mutations (mean ± s.e.m.: 18.4 ± 2.8 versus 9.3 ± 1.0, fold change (FC) = 1.98, P = 2.0× 10 −6 by a two-tailed U-test, Fig. 3a) , whereas no significant difference was observed in unaffected siblings (mean ± s.e.m.: 7.9 ± 1.0 versus 11.4 ± 1.3, FC = 0.69, P = 0.60). This suggests that interaction-disrupting dnMis mutations in ASD probands preferentially impact hub proteins, which play a central role in maintaining the integrity of the human interactome 52 . Importantly, when we excluded essential human genes 53 from our analysis, the correlation between interaction-disrupting dnMis mutations and protein hubs persisted in probands (mean ± s.e.m.: 17.6 ± 2.9 versus 9.2 ± 1.0, FC = 1.91, P = 7.2 × 10
, Fig. 3a) . Similarly, no such correlation was observed in unaffected siblings (mean ± s.e.m.: 8.0 ± 1.0 versus 11.0 ± 1.3, FC = 0.73, P = 0.50). Likewise, when we analyzed betweenness, another measure of network centrality based on shortest paths, proteins harboring interaction-disrupting dnMis mutations have a significantly higher betweenness value than proteins harboring non-disrupting dnMis mutations in ASD probands, regardless of whether essential genes were included (Fig. 3b) .
To further assess whether disruptive dnMis mutations tend to be on essential genes, we analyzed gene essentiality measured using CRISPR (clustered regularly interspaced short palindromic repeat) gene knockout screens 54 . Using this CRISPR score, we observed no significant difference in essentiality between genes with interaction-disrupting and non-disrupting dnMis mutations for probands (mean ± s.e.m.: − 0.43 ± 0.08 versus − 0.33 ± 0.04, FC = 1.30, P = 0.28 by a two-tailed U-test) or for unaffected siblings (mean ± s.e.m.: − 0.37 ± 0.09 versus − 0.41 ± 0.05, FC = 0.90, P = 0.39). This confirms that disruptive dnMis mutations have no tendency to be on essential genes while preferentially affecting topologically central positions in the interactome network in ASD probands.
We then investigated whether proteins with dnMis mutations tend to form inter-connected modules within the interactome network. We found that in ASD probands, proteins with interaction-disrupting dnMis mutations on average have a significantly smaller shortest path length to each other than proteins harboring non-disrupting dnMis mutations (mean ± s.e.m.: 3.48 ± 0.04 versus 3.94 ± 0.03, FC = 0.88, P = 3.9 × 10 −18 by a two-tailed U-test, Fig. 3c ). This result indicates that proteins with disruptive dnMis mutations in probands tend to be closely connected to each other in the network and may therefore function as modules with specific roles in ASD etiology. In contrast, no such trend was observed for proteins with disruptive dnMis mutations in unaffected siblings (mean ± s.e.m.: 3.77 ± 0.05 versus 3.79 ± 0.03, FC = 0.99, P = 0.96), underscoring the functional significance of modules derived from interaction-disrupting dnMis mutations in ASD probands. ). Comparing disruption rates between males and females showed a higher rate, although not significant, in females than males in ASD probands (FC = 1.71 (0.71-4.09, 95% CI), P = 0.12 by a one-tailed negative binomial test), whereas similar rates were observed in female and male siblings (FC = 1.08 (0.52-2.22, 95% CI), P = 0.42).
Overall, our results indicate that network topology should be considered when interpreting the impact of dnMis mutations. By analyzing network properties, we can investigate how individual disruptive missense mutations locally alter protein complexes and functional modules and how multiple mutations work together to rewire the whole cellular network which can, as a result, lead to autism or other disease-associated phenotypes.
Disruptive dnMis mutations and haploinsufficient genes.
Disruptive dnMis mutations typically occur only on one copy of the gene. To affect risk, they should occur more frequently on haploinsufficient genes, where a single copy of the wild-type gene is insufficient to carry out its normal function. In probands, genes harboring interaction-disrupting dnMis mutations have a significantly higher probability of being haploinsufficient 55 than genes harboring nondisrupting dnMis mutations (mean ± s.e.m.: 0.42 ± 0.03 versus 0.33 ± 0.02, FC = 1.27, P = 1.6× 10 −3 by a two-tailed U-test, Fig. 3d ). In contrast, no significant difference was observed in unaffected siblings (mean ± s.e.m.: 0.39 ± 0.04 versus 0.34 ± 0.02, FC = 1.15, P = 0.27). Reinforcing these findings, we also found that genes with interaction-disrupting dnMis mutations in probands are less tolerant to genetic variation, as indicated by their higher average pLI 56 scores in comparison to genes with non-disrupting dnMis mutations (mean ± s.e.m.: 0.52 ± 0.04 versus 0.43 ± 0.02, FC = 1.21, P = 0.02, Fig. 3e ). No such contrast was found in unaffected siblings (mean ± s.e.m.: 0.44 ± 0.06 versus 0.44 ± 0.03, FC = 1.00, P = 0.57).
Collectively, these results demonstrate that interaction-disrupting dnMis mutations in ASD probands tend to affect haploinsufficient genes, for which heterozygous variations are not tolerated, and they may therefore contribute to ASD outcomes through dosage effect 57 .
Disruptive dnMis mutations in probands cluster to ASD genes.
To evaluate whether interaction-disrupting dnMis mutations are associated with ASD risk, we first investigated whether such mutations are enriched in previously reported ASD-associated genes. Using a curated list of 881 genes implicated in ASD in the SFARI database 58 , we observed a significant enrichment in probands for genes with interaction-disrupting dnMis mutations compared to genes with non-disrupting dnMis mutations (21/109 versus 32/342, odds ratio (OR) = 2.3, P = 5.7× 10 −3 by a one-tailed Fisher's exact test, Supplementary Table 3 ). In contrast, no significant enrichment was observed in unaffected siblings (6/68 versus 17/241, OR = 1.3, P = 0.39). Thus, characterizing interaction perturbation captures new evidence to establish associations of genes with ASD.
Previous studies have reported functional clustering in genes with de novo protein-truncating variants (dnPTVs) in ASD individuals 13, 14, 16, 59 . Here we assessed the network distance within the human interactome between genes harboring interactiondisrupting dnMis mutations (excluding genes with dnPTVs) . Genes carrying dnPTVs in SSC data were excluded from all analyses. Violin plots: thick black bar, interquartile range; white dot, median; whiskers, upper and lower limits; points, outliers; the width of each 'violin' is proportional to element abundance. P values were calculated using a two-tailed U-test (*P < 0.05).
and seven classes of known ASD-associated genes. These genes (Supplementary ); and the latest set of 65 ASD genes discovered by de novo mutations 29 . We found that in probands, proteins harboring interaction-disrupting dnMis mutations are significantly closer to proteins from all seven classes in comparison to proteins with non-disrupting dnMis mutations (Table 1 and Supplementary Note; Methods). In contrast, no significant differences were observed among unaffected siblings in any category. These findings demonstrate that disruptive dnMis mutations identified by our study in ASD probands are indeed closely related to known ASD genes and functional classes and that they may contribute to ASD etiology by disrupting common pathways shared with dnPTVs.
Identification of candidate ASD genes and mutations. Towards the identification of new candidate ASD-associated genes, we examined mutations on the protein RARA (Supplementary Note). RARA binds with RXRB to form the retinoic acid receptor complex. When bound to retinoic acid, the retinoic acid receptor can then bind retinoic acid receptor elements to co-activate transcription of downstream genes. In agreement with our Y2H experiments, our computational approach predicted that a proband mutation p.Pro375Leu on RARA (NP_000955.1) is disruptive, while an unaffected sibling mutation, p.Arg83His, is not (Fig. 4a,b) . We note that PPH2 predicts both mutations to be probably damaging and cannot distinguish the two. We further confirmed by co-immunoprecipitation in human cells that the proband mutation p.Pro375Leu disrupts the RARA-RXRB interaction while the sibling mutation p.Arg83His does not ( Fig. 4c; Methods) .
While there is insufficient evidence to directly link mutations on RARA to ASD, there is compelling evidence that mutated RARA does induce ASD risk by affecting retinoic acid signaling. Specifically, we would expect the p.Pro375Leu mutation to diminish retinoic acid signaling by disrupting its binding to RXRB. Notably, one of the most common genetic risk factors for ASD is maternal duplication of 15q11-q13 and isodicentric chromosome 15 60 , both of which increase transcription of UBE3A, among other genes. It has recently been shown that UBE3A negatively regulates ALDH1A proteins 61 , which act as rate-limiting enzymes in retinoic acid synthesis. Increased dosage of UBE3A diminishes retinoic acid synthesis and retinoic acid signaling, altering neuronal development and features such as homeostatic synaptic plasticity 61 . Moreover, in mice, ASD-like phenotypes are induced by overexpression of UBE3A or by an ALDH1A antagonist, while the wild-type phenotype can be rescued by retinoic acid supplementation 61 . Thus, together with published results regarding the role of UBE3A in retinoic acid signaling and autism risk 61 , our results implicate RARA as an ASD-associated gene, and our experimentally validated interaction-disrupting prediction for RARA p.Pro375Leu demonstrates how our methodology can be used to identify functional dnMis mutations.
The occurrence of a predicted disruptive mutation near other closely related disease-associated dnMis mutations across interacting proteins can lend strong evidence towards the postulated functionality and shared phenotypic impact of the mutation in question. In this regard, our computational approach predicted an ASD proband mutation, p.Lys1431Met, on the guanine nucleotide exchange factor TRIO (NP_651960.2) that disrupts its interaction with the GTPase RAC1 (Fig. 4d) . Of note, two neurodevelopmental disorder dnMis mutations 18, 62 on TRIO, p.Arg1428Gln and p.Pro1461Leu, occur in structural proximity to the ASD proband interface mutation, p.Lys1431Met, as do three dnMis mutations on RAC1 (NP_008839.2) interface residues, p.Asn39Ser, p.Tyr64Asp and p.Pro73Leu, which all result in mild to severe intellectual disability 63 ( Fig. 4d) . Moreover, p.Lys1431Met has recently been reported to functionally inhibit synaptic function in human cell lines and statistically postulated to reside within a hotspot for ASD-related de novo mutations in the GEF1 domain of TRIO 64 . As sequencing data from developmental disorder studies become more readily available, we anticipate the use of predicted interaction-disrupting mutations to uncover shared molecular pathways between related developmental disorders. dnMis mutations in other developmental disorders. To demonstrate the generalizability of our interactome perturbation approach towards studying the impact of missense mutations in human disease, we investigated how ~10,000 dnMis mutations previously detected in developmental disorders correspond with protein interaction interfaces. The mutation data comprise a collection of 4,565 dnMis mutations from the Deciphering Developmental Disorders project and five lists of dnMis mutations curated from studies of autism, congenital heart disease, intellectual The number of genes in each class is indicated in parentheses. Genes carrying dnPTVs in SSC data were excluded from the analyses. P values were calculated using a one-tailed U-test (P < 0.05 in bold). Dis, interaction-disrupting; Non-Dis, non-disrupting. FMRP, fragile X mental retardation protein target genes; CHM, genes encoding chromatin modifiers; EMB, genes expressed preferentially in embryos; PSD, genes encoding postsynaptic density proteins; SFARI, 881 genes in the SFARI database; SFARI hq, a high-quality SFARI subset (141 genes scored as syndromic, high confidence or strong candidate); DN65, the latest set of 65 ASD genes discovered by de novo mutations.
disability, schizophrenia and epilepsy (denovo-db v.1.5) 65 . We found that in all six data sets, dnMis mutations occur significantly more frequently on protein interaction interfaces than expected (Fig. 5) , indicating that dnMis mutations in developmental disorders can contribute to disease risk by impacting protein interactions. In particular, the strongest signal was observed in intellectual disability: 23.5% of the dnMis mutations occurred on interaction interfaces, resulting in an enrichment of 2.09 (1.77-2.44, 95% confidence interval (CI)) in comparison to the fraction of interface residues on corresponding proteins (11.2%, P = 1.4× 10 −14 by a two-tailed exact binomial test). In contrast, dnMis mutations in schizophrenia had the weakest significance (enrichment = 1.61 (1.22-2.06, 95% CI), P = 8.7× 10 -4 ), which agrees with previous findings that schizophrenia has a much weaker de novo signal than other developmental disorders 66 . Forty dnMis hotspots implicated in neurodevelopmental disorder pathogenesis have recently been reported 67 . When we examined the 31 corresponding hotspots within the interactome network, we found that they occur on protein interaction interfaces at a very high rate of 48.4% (enrichment = 4.03 (2.51-5.58, 95% CI), P = 6.9× 10
, Fig. 5 ). This suggests that interactome perturbations play an important role in the pathogenesis linked with these recurrent events. Taken together, these findings reinforce that our integrated experimental-computational interactome perturbation approach offers a scalable and generalizable framework to identify risk dnMis mutations in human disease. Intellectual disability, microcephaly p.Arg1428Gln
Intellectual disability p.Tyr64Asp
Intellectual disability, microcephaly p.Pro73Leu
Intellectual disability, microcephaly p.Asn39Ser
Intellectual disability p.Pro1461Leu 
Discussion
Here we demonstrated that dnMis mutations can contribute to ASD risk by disrupting protein-protein interactions and that our interactome perturbation framework offers a novel and effective way to identify ASD risk dnMis mutations. As only a small fraction of dnMis mutations found in ASD subjects are believed to be functional 12 , this framework helps overcome a significant challenge in identifying risk dnMis mutations. Our analyses focused on dnMis mutations from the SSC families because the information on unaffected siblings in the data set provides robust negative controls. Our results demonstrated that interaction-disrupting dnMis mutations in ASD probands preferentially impact proteins that have many interaction partners in the interactome network (that is, hubs) and disrupt these interactions at a significantly higher rate than those in unaffected siblings. Our results also lend evidence to previously reported ASD-associated genes and pathways by showing that interaction-disrupting dnMis mutations are closely clustered to proteins in ASD-associated functional classes in the interactome network. Thus, characterizing interactome perturbation provides additional and potentially orthogonal information to strengthen previously identified genetic associations and helps in the discovery of new genes that contribute to ASD risk.
Integration of computational predictions with experimental data imbued more meaning onto missense mutations found in ASD probands and their siblings. Thus, the prediction model alone can enhance researchers' ability to prioritize damaging missense mutations and can be applied across a wide range of human disease studies. We emphasize that the strength of this prediction model is rooted in its integration of PPH2 scores and Interactome INSIDER interface predictions. To demonstrate this, we repeated all analyses using PPH2 and Interactome INSIDER separately. The results show that neither method individually is sufficient to reproduce most signals towards identifying disease-contributing dnMis mutations in ASD ( Supplementary Fig. 2 and Supplementary Fig.  3 ). This confirms that our two-tiered predictor, which evaluates the disruptiveness of a variant on protein interactions, greatly improves the effectiveness of predicting functional missense mutations. We also note that our predictor is robust at different PPH2 score cutoffs (Supplementary Fig. 4 ). Taken together, we demonstrate that our computational prediction approach can serve as an effective and robust method to identify disease-contributing missense mutations.
Stronger associations between ASD proband mutations and clinical data can be established by filtering out ASD dnMis mutations that are also identified as population variants in the Exome Aggregation Consortium (ExAC) 56 since these variants represent standing variations in the population and are less likely to be deleterious as a result 68 . Adopting this same principle, we found that dnMis mutations in developmental disorders are significantly more enriched on interaction interfaces when mutations coinciding with ExAC are filtered out in comparison to the non-filtered set ( Supplementary Fig. 5 and Supplementary Note). Importantly, our results show that the characteristic network and haploinsufficiency properties of disruptive proband dnMis mutations are not unique to ASD but are shared features across different developmental disorders (Supplementary Fig. 6 ), indicating that our interactome perturbation framework is generalizable to prioritize dnMis mutations across a wide range of developmental disorders (Supplementary Note).
Our analyses indicate that network properties are important in interpreting the functional impact of dnMis mutations and their relevance towards disease etiology. However, we recognize that the human interactome with which these analyses are performed is currently incomplete. As a result, certain classes of protein interactions, for example interactions mediated by membrane-bound proteins, may be under-represented in the current interactome, limiting potential insights from such proteins. Moreover, literaturederived segments of the human interactome are subject to sampling bias present in small-scale studies 38, 69 . Therefore, we re-examined the network topology analyses across a chronologically ordered series of unbiased high-throughput-derived human interactomes (Supplementary Note). Not only do we show that our results are robust across all high-throughput-derived interactomes, more importantly, we also demonstrate that the topological differences between interaction-disrupting and non-disrupting dnMis mutations in probands become more significant as the interactome coverage increases (Supplementary Fig. 7) . Moreover, we show that all of our results remain the same when we expanded our disruptiveness predictions to include all dnMis mutations in the current human interactome ( Supplementary Fig. 8 and Supplementary Note). Taking these results together, we fully expect that as increasingly more human protein-protein interactions and mutations are uncovered, our interactome perturbation framework can be applied to these new interactions and mutations to identify new or currently under-characterized disease-associated mutations and genes.
As large-scale WES studies continue to produce mutation data at ever-increasing scales, our interaction-disruption prediction approach can greatly extend the reach of interactome perturbation studies to investigate complex genotype-phenotype relationships and improve our understanding of how genetic variation affects disease risk through the alteration of topological and community structures of networks.
URLs. Interactome INSIDER predictions, http://interactomeinsider.yulab.org; SFARI database (downloaded on June 6, 2017), https://gene.sfari.org/database/human-gene/; denovo-db (v.1.5), http://denovo-db.gs.washington.edu/denovo-db/Download.jsp.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0130-z. 
Enrichment of dnMis mutations on interaction interfaces. The set of 412 proteins with dnMis mutations and containing at least 1 interaction interface and 1 known domain was included for calculating dnMis mutation distribution. The sequences were divided into three regions: 'in interaction interface' , 'in other domain' and 'outside domains' . Interaction interfaces were determined by our previously developed human structural interaction network (hSIN 36 , comprising 4,222 structurally resolved interactions between 2,816 proteins). 'Other domains' referred to protein domains (obtained from Pfam 70 database) that exclude interacting interfaces in hSIN. The rest of the residues then were categorized as 'outside domains' . If the locations of mutations were not influenced by the domain architecture of the protein, then their relative lengths should determine the frequency of mutations in these three regions. The fraction of mutations expected by chance in each region was calculated by adding the total sequence length of each region in all proteins, and dividing it by the length of all proteins combined; call the probability of falling in an interaction interface p. The number of observed mutations in each region over all proteins was also computed; call the number falling in the interaction interfaces S, and let N be the total number of dnMis missense mutations. An exact binomial test was then computed from p, S and N. CIs are based on the 95% CI for an exact binomial, and then transformed to the risk ratio (enrichment) using the expectation in the denominator and the lower/ upper bound in the numerator.
In ASD probands, the total length of 248 proteins is 377,421, which compromises 113,449 residues on interaction interfaces, 69,870 residues on other domains and 194,102 residues outside domains. The probabilities for a mutation to fall in these regions were computed to be 30.1%, 18.5% and 51.4%, respectively. The observed distribution of the 296 dnMis mutations on these proteins was 113 on interaction interfaces, 59 on other domains and 124 outside domains, showing that dnMis mutations in ASD probands are significantly enriched on protein interaction interfaces (enrichment = 1.27 (1.09-1.46, 95% CI), P = 2.9 × 10 Cloning of 208 dnMis mutations using our massively parallel Clone-seq pipeline. Single-colony-derived mutant clones were constructed using a highthroughput mutagenesis and next-generation sequencing pipeline called Cloneseq 24 ( Supplementary Fig. 9 ). Wild-type clones were picked from hORFeome v8.1 71 to serve as templates for site-directed mutagenesis (Eurofins). Mutagenesis was performed at 96-well scales using site-specific mutagenesis primers and full-length human ORF templates. PCR product was digested overnight using DpnI (NEB) without a ligation step to maximize throughput and then transformed directly into competent cells to isolate single colonies. Then, 4 colonies per mutagenesis reaction were hand-picked and arrayed into 96-well plates. After 21 h incubation at 37 °C, glycerol stocks were generated and then clones were pooled into 4 respective bacterial pools. Maxiprepped DNAs from each of the 4 pools were then combined through multiplexing (NEBNext) and then sequenced in a single 1 × 100 singleend Illumina HiSeq run. Properly mutated clones were then identified by nextgeneration sequencing analysis and recovered from single-colony glycerol stocks. In total, we generated individual clones for 208 dnMis mutations comprising 109 from ASD probands and 99 from unaffected siblings.
Experimental examination of 667 protein-protein interactions using our highthroughput Y2H assay. To perform Y2H, pDEST-AD and pDEST-DB plasmid vectors corresponding to the GAL4-activating domain (AD) and DNA-binding (DB) domain, respectively, were used. Full-length Clone-seq-identified mutant clones were transferred into Y2H-amenable pDEST-DB and pDEST-AD vectors by Gateway LR reactions and then transformed into MATα Y8930 and MATa Y8800, respectively. All DB-ORF MATα transformants, including wild-type ORFs, were then mated against corresponding wild-type and mutant AD-ORF MATa transformants in a pairwise orientation on YEPD agar plates. After mating, yeast was replica-plated onto selective SC-Leu-Trp-His+ 1 mM of 3-amino-1,2,4-triazole (3AT) as well as SC-Leu-Trp-Adenine plates. Interactions were scored after three days of incubation and five days of incubation for SC-Leu-Trp+ 3AT and SC-Leu-Trp-Ade plates, respectively. To screen out autoactivating DB-ORFs, all DB-ORF MATα transformants were also mated pairwise against empty pDEST-AD MATa transformants and scored for growth on SC-Leu-Trp+ 3AT and SCLeu-Trp-Ade plates. DB-ORFs that trigger reporter activity under this setup were removed from further experiments. We finally examined 667 interactions, of which the wild-type proteins could be detected with strong Y2H-positive phenotypes in our experiments, for 151 out of the 208 total dnMis mutations that we have successfully generated. The other 57 dnMis mutations corresponded to proteins with no testable interaction partners by Y2H; therefore, they were excluded from Y2H experiments. While on average each of the 151 mutations was tested against 4 or 5 interaction partners, 2 proband mutations (Q8TBB1 p.Glu295Lys and Q8TD31 p.Trp337Arg) had > 40 interaction partners tested and disrupted > 30 of their corresponding interactions. Thus, we excluded these two outliers when comparing the disruption rates of dnMis mutations in ASD probands and unaffected siblings (Fig. 2a) .
Let n 1 and n 2 be the number of genes in L 1 and
Then consider i and j as two nodes in the interactome network; the distance between these two nodes Distance(i, j) here is defined as the minimum number of intermediate nodes that connect i and j in the shortest path.
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability. dnMis mutations in ASD subjects and their unaffected siblings came from published data in ref. 12 and are available in Supplementary 
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